{"schema":"sb.node.v1","id":"sb:e/41fbf30f144487f9b881466a","kind":"entity","label":{"text":"her2-positive","locale":"en"},"identity":{"anchor":"label:en:her2-positive","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T15:54:56.699691+00:00","snapshot":"deploy 5dd6bfa537b0d111fd487bdb898acfd5f7a13cfd"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":39,"separatePublishers":14,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.636,"named":7,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-05-05","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.231: about 77% of mentions carry no typed assertion"]}},"dimensions":{"domains":["society_news","precision_medicine"],"activeDays":22,"assertions":{"regulatory-approval":8,"acquisition":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":7,"byKind":{"observation":7},"withheld":{"state":"withheld","count":5,"offTopic":4,"reason":"5 receipts not served: 4 off topic: the receipt's own headline does not name the subject (the document mentions it elsewhere, so it is counted in standing.evidence.supporting, but it is not a receipt about the subject); 1 withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/6164cd5c9362b09700f9ad34","kind":"observation","label":"medRxiv Oncology · 2026-10-07 · Multimodal Artificial Intelligence Predicts Pathological Response and Prognosis in HER2-Positive Early Breast Cancer Treated with Chemotherapy De-escalation Strategies…","url":"https://www.medrxiv.org/content/10.64898/2026.10.05.26364736v1?rss=1"},{"id":"sb:o/6118c418b7e4dab053c5be12","kind":"observation","label":"FDA · 2026-10-07 · FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer"},{"id":"sb:o/519d9a8a2891f95f40ad3c3a","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-25 · Individualized treatment of HER2-positive breast cancer patients with lung metastasis using a circulating tumor cell drug sensitivity test: a case report","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1888730"},{"id":"sb:o/098b843e301c3ec077063e95","kind":"observation","label":"Nature Medicine · 2026-09-22 · Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial","url":"https://www.nature.com/articles/s41591-026-04679-x"},{"id":"sb:o/4dfd5a71177aa3b90efa9b2f","kind":"observation","label":"The ASCO Post · 2026-09-04 · Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer","url":"https://ascopost.com/news/september-2026/predictors-of-pcr-to-neoadjuvant-thp-explored-in-her2-positive-breast-cancer/"},{"id":"sb:o/dc88be5f2f59bd1b5e8d8ede","kind":"observation","label":"FDA Drug News · 2026-06-25 · [APPROVAL] FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metast…","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-palbociclib-trastuzumab-or-without-pertuzumab-and-endocrine-therapy-maintenance"},{"id":"sb:o/870e5dda96c351a5ed1ca128","kind":"observation","label":"FDA Drug News · 2026-05-16 · [APPROVAL] FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage"}],"cursor":null,"order":"newest first; we keep the 7 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":{"state":"cannot-measure","reason":"claims: this subject's maintained record could not be read (the maintained record \"her2-positive\" could not measure its claims: this subject was retired from the publication registry on 2026-09-30 (no longer clears the admission conditions — re-checked 2026-09-30 (no receipt in the corpus-evidence shard for this label)); the record is kept as a dated tombstone and is no longer maintained). The items listed come from the passes that could be read"},"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with her2 (39 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d453bb0dbf62bdcf3d1b5abf"},{"kind":"relation","label":"co-mentioned with breast cancer (23 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4c5de58acf83c24a9b43cd30"},{"kind":"relation","label":"co-mentioned with colorectal cancer (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/db8d71f255f4927c49e1ae86"},{"kind":"relation","label":"co-mentioned with immunotherapy (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/96dff68d86c160ed6a426bed"},{"kind":"relation","label":"co-mentioned with studie (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8b7143c29aeea9ad79daa897"},{"kind":"relation","label":"co-mentioned with fda (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/05a3219ba50d9a26076b6c6b"},{"kind":"relation","label":"co-mentioned with asco (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5af795e7bb417094fbde1baf"},{"kind":"relation","label":"co-mentioned with ai (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/822f38c4c54c9c0f468ba8e3"},{"kind":"relation","label":"co-mentioned with her2-directed (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/171f413f7b86a2672f4fe934"},{"kind":"relation","label":"co-mentioned with her2-negative (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/98d592e499c6ac0b581c320d"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/41fbf30f144487f9b881466a","mcp":"traverse {\"id\":\"sb:e/41fbf30f144487f9b881466a\"}","page":"/entity/her2-positive/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/41fbf30f144487f9b881466a\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/41fbf30f144487f9b881466a\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/41fbf30f144487f9b881466a\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/41fbf30f144487f9b881466a\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}